-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Firing Up COLD Tumor Microenvironment to Facilitate GVL

Program: Scientific Program
Session: Host Factors Driving Anti-Leukemia Immunotherapy Outcomes
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, AML, Diseases, Immune mechanism, Treatment Considerations, Biological therapies, Immunotherapy, Myeloid Malignancies, Biological Processes, Transplantation (Allogeneic and Autologous)
Saturday, December 7, 2024, 2:00 PM-3:15 PM

Takanori Teshima, MD, PhD

Hokkaido University, Sapporo, Hokkaido, Japan

Disclosures: Teshima: Takeda: Consultancy, Honoraria; Roche Diagnostics: Consultancy; Gilead: Honoraria; Pfizer: Honoraria; AstraZeneca: Honoraria; Chugai: Honoraria, Research Funding; Sanofi: Honoraria; MSD: Honoraria; Fuji Pharma: Honoraria, Research Funding; Symbio: Honoraria; Nippon Kayaku: Honoraria, Research Funding; Meiji Seika Pharma: Consultancy, Honoraria; Pharma Essentia Japan: Research Funding; LUCA Science: Research Funding; Shionogi: Honoraria, Research Funding; Novartis: Honoraria; Otsuka: Honoraria, Research Funding; Astellas: Honoraria, Research Funding; Eisai: Research Funding; Abbvie: Honoraria; Janssen: Honoraria; Nippon Shinyaku: Consultancy, Honoraria; Asahi Kasei Pharma: Honoraria, Research Funding; Kyowa-Kirin: Consultancy, Honoraria, Research Funding; Genmab: Honoraria; Sumitomo Pharma: Research Funding; Bristol-Myers Squibb: Honoraria; Daiichi Sankyo: Honoraria, Research Funding; JCR Pharma: Honoraria, Research Funding.

See more of: Host Factors Driving Anti-Leukemia Immunotherapy Outcomes
See more of: Scientific Program
<< Previous Presentation | Next Presentation >>